The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
Total excision of the ureter with a bladder cuff, renal pelvis, and kidney is recommended to provide the greatest likelihood of cure.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
Most patients with renal pelvic transitional cell cancers and ureteral cancers undergo total nephroureterectomy with bladder cuff excision. This treatment is because of the rarity of synchronous bilateral renal pelvic neoplasia, the low incidence of asynchronous development of contralateral upper tract tumors, and the increased risk of tumor recurrence in the ipsilateral ureter distal to the original pelvic tumor.
Contemplation of anything less than total excision must take into account the potential risk for tumor recurrence anywhere in the upper tract unit. In other than unifocal, low-grade, low-stage renal pelvic tumors, the probable extensive involvement of both contiguous and noncontiguous sites would appear to make segmental excision an unnecessary option with a potentially serious risk. However, an operative possibility includes segmental excision of a particular lesion. If the extent of a tumor can be determined by intraoperative assessment and frozen section histological diagnosis confirms a low-grade, unifocal tumor of limited size, then segmental excision is possible. However, this approach should be reserved for highly selected patients such as patients with one kidney or those with decreased renal function who require maximal preservation of renal tissue. The likelihood of tumor recurrence in this setting, and of extension of disease outside the renal pelvis once the pelvis has been violated, is a serious risk that must be heavily weighed in offering a patient this therapeutic option.
Ureteral transitional cell cancer may more readily offer the possibility of segmental excision if the absence of proximal disease can be documented. In this setting, attention is focused on the ease of reconstruction of the ureter and restoration of ureterovesical continuity. This treatment is most feasible if the cancer is in the distal ureter. If partial ureterectomy is possible and proximal disease has been excluded, then segmental excision and ureteral reimplantation can be performed.
Systematic regional lymph node dissection in conjunction with nephroureterectomy or segmental excision has not been found to enhance the effectiveness of surgery if tumors are of high grade or high stage because, in these instances, the overall results are so poor. Correspondingly, lymph node involvement is uncommon in low-stage disease, and lymphadenectomy is unlikely to remove additional tumor. Lymph node dissection at the time of nephrectomy may offer prognostic information, but little, if any, therapeutic benefit.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
Treatment options for localized transitional cell cancer of the renal pelvis and ureter include the following:
Nephroureterectomy with bladder cuff excision.
Segmental resection of ureter, only if the tumor is superficial and located in the distal third of the ureter.
Electroresection and fulguration or laser fulguration, if the tumor is superficial (under clinical evaluation).
Any parenchymal sparing procedure (segmental resection; ureteroscopic or percutaneous resection/fulguration/laser destruction), if the renal unit is solitary or renal function is depressed (under clinical evaluation).
Intrapelvic or intraureteral cytotoxic/immunotherapy (under clinical evaluation). The dramatic success reported with intravesical cytotoxic (thiotepa, mitomycin, doxorubicin) or immunologic/inflammatory (Bacillus Calmette Guerin [BCG], interferon) therapy for superficial transitional cell cancers in the bladder has led to the occasional use of these agents in the treatment of upper tract cancers. Long-term follow-up of the results of such treatments has generally not been reported. The efficacy of this approach cannot be assessed, largely because experience has been limited to patients whose compromised clinical status (solitary kidney, renal failure, medical risks for surgery) may have influenced clinical outcome. The use of this approach is limited by the following:
Intrapelvic or intraureteral cytotoxic/immunotherapy (under clinical evaluation). The dramatic success reported with intravesical cytotoxic (thiotepa, mitomycin, doxorubicin) or immunologic/inflammatory (Bacillus Calmette Guerin [BCG], interferon) therapy for superficial transitional cell cancers in the bladder has led to the occasional use of these agents in the treatment of upper tract cancers. Long-term follow-up of the results of such treatments has generally not been reported. The efficacy of this approach cannot be assessed, largely because experience has been limited to patients whose compromised clinical status (solitary kidney, renal failure, medical risks for surgery) may have influenced clinical outcome. The use of this approach is limited by the following:
The extent of disease in the renal pelvis.
The access that these agents may have to the area of disease.
The sensitivity of the cancer being treated.
The adequacy and accuracy of initial tumor staging and continued monitoring.
Laser vaporization/coagulation (under clinical evaluation). Transurethral and percutaneous access to the upper tract have permitted the use of laser therapy in the control of superficial upper tract transitional cell cancers. This approach is dependent on accurate staging and adequate visualization of the lesions that need to be coagulated. Results of this approach are too preliminary to assess. Therapeutic efficacy, however, will depend on staging accuracy at initial treatment and the ease of monitoring such patients for disease recurrence and possible progression.
The development of new instrumentation for endourological treatment of upper tract transitional cell cancer has provided new options for regional management of these cancers. Introduction of electrofulguration and resection instruments or laser probes either transureterally or percutaneously, may permit destruction of a primary cancer. Introduction of cytotoxic agents has also been used. Although a biopsy can be taken for staging purposes, its accuracy remains to be determined. The efficacy of treatment by these maneuvers has not been established.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
There is no well-documented success for treatment of extensive regional disease with either radiation therapy or systemic chemotherapy. Patients with extensive regional disease should consider clinical trials.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 5, 2024. Captured 2026-09-09.
The prognosis for any patient with metastatic or recurrent transitional cell cancer is poor. The proper management of recurrence depends on the sites of recurrence, extent of prior therapy, and individual patient considerations. Chemotherapy regimens that have been effective for metastatic bladder cancer have generally been applied to transitional cell cancers arising from other sites. Patients with distant metastases have a poor prognosis and can be offered treatment in a clinical trial.
In patients with metastatic or recurrent transitional cell carcinoma of the bladder, combination chemotherapy has produced high response rates and occasional complete responses.[1,2] Results from a randomized trial that compared methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) with single-agent cisplatin in advanced bladder cancer showed a significant advantage with M-VAC in both response rate and median survival. The overall response rate with M-VAC in this cooperative group trial was 39%.[3]
Other chemotherapy agents that have shown activity in metastatic transitional cell cancer include the following:[4-8][Level of evidence C3]
Sources: 4 · 8 · Level of evidence C3
Paclitaxel.
Ifosfamide.
Gallium nitrate.
Gemcitabine.
Pemetrexed.
Ifosfamide, gallium nitrate, and pemetrexed have shown limited activity in patients previously treated with cisplatin.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The treatment options depend on:
the stage and grade of the tumor
where the tumor is
whether the patient's other kidney is healthy
whether the cancer has recurred (come back)
Most transitional cell cancer of the renal pelvis and ureter can be cured if found early.
Sources: cured
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There are different types of treatment for patients with transitional cell cancer of the renal pelvis and ureter.
The following type of treatment is used:
The following type of treatment is used:
Surgery
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Fulguration
Segmental resection of the renal pelvis
Treatment for transitional cell cancer of the renal pelvis and ureter may cause side effects.
Follow-up care may be needed.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Different types of treatments are available for people with transitional cell cancer of the renal pelvis and ureter. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You’ll want to learn what you need to do before treatment begins, how you’ll feel while going through it, and what kind of help you will need. To learn more, see Questions to Ask Your Doctor about Treatment.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
One of the following surgical procedures may be used to treat transitional cell cancer of the renal pelvis and ureter:
Nephroureterectomy is surgery to remove the entire kidney, the ureter, and the bladder cuff (tissue that connects the ureter to the bladder). Most people with transitional cell cancer of the renal pelvis and ureter undergo nephroureterectomy.
Segmental resection of the ureter is a surgical procedure to remove the part of the ureter that contains cancer and some of the healthy tissue around it. The ends of the ureter are then reattached. This treatment is used when the cancer is superficial and in the lower third of the ureter only, near the bladder.
Sources: superficial
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Fulguration is a surgical procedure that destroys tissue using an electric current. A tool with a small wire loop on the end is used to remove the cancer or to burn away the tumor with electricity.
Sources: Fulguration
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
This is a surgical procedure to remove localized cancer from the renal pelvis without removing the entire kidney. Segmental resection may be done to save kidney function when the other kidney is damaged or has already been removed.
Sources: localized · kidney function
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
A laser beam (narrow beam of intense light) is used as a knife to remove the cancer. A laser beam can also be used to kill the cancer cells. This procedure may also be called laser fulguration.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. To learn more about chemotherapy, see Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Immunotherapy helps a person’s immune system fight cancer. Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Regional treatment for transitional cell cancer of renal pelvis and ureter is a method of placing the chemotherapy or immunotherapy drug directly into the renal pelvis or the ureter to mainly affect cancer cells in those areas.
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of localized transitional cell cancer of the renal pelvis and ureter may include:
Sources: localized
surgery (nephroureterectomy or segmental resection of ureter)
Sources: nephroureterectomy · segmental resection
a clinical trial of fulguration
Sources: clinical trial · fulguration
a clinical trial of laser surgery
Sources: laser surgery
a clinical trial of segmental resection of the renal pelvis
a clinical trial of regional chemotherapy or regional immunotherapy
Sources: regional chemotherapy
To learn more about these treatments, see the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of regional transitional cell cancer of the renal pelvis and ureter is usually done in a clinical trial.
Sources: regional · clinical trial
To learn more about clinical trials, see the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of metastatic or recurrent transitional cell cancer of the renal pelvis and ureter is usually done in a clinical trial, which may include chemotherapy.
Sources: metastatic · recurrent · clinical trial
To learn more about clinical trials, see the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
ClinicalTrials.gov recordCarcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
ClinicalTrials.gov recordCarcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
ClinicalTrials.gov recordBladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
ClinicalTrials.gov recordBladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
ClinicalTrials.gov recordAdenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer,...
ClinicalTrials.gov recordBladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
ClinicalTrials.gov recordAdenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer,...
ClinicalTrials.gov recordDistal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage...
ClinicalTrials.gov recordDistal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell...
ClinicalTrials.gov recordCarcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
ClinicalTrials.gov recordTransitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
ClinicalTrials.gov recordUrothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
ClinicalTrials.gov recordLocally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral...
ClinicalTrials.gov recordTransitional Cell Carcinoma